Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 2, 2006, Pages 157-159

  Korzenik, Joshua R ^a   Podolsky, Daniel K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

COLON CROHN DISEASE; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HOMEOSTASIS; HUMAN; MORTALITY; NONHUMAN; PRESCRIPTION; ULCERATIVE COLITIS; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; PYRAZOLES; SULFONAMIDES;

EID: 32044475177     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2005.11.007     Document Type: Editorial

References (18)

1. M.M. Wolfe, D.R. Lichtenstein, G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888 1899
2. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
3. H.J. Kaufmann, H.L. Taubin Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease Ann Intern Med 107 1987 513 516
4. D.S. Rampton, G.E. Sladen Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs Postgrad Med J 57 1981 297 299
5. J.M. Evans, A.D. McMahon, F.E. Murray Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease Gut 40 1997 619 622
6. G.F. Bonner, A. Fakhri, S.R. Vennamaneni A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease Inflamm Bowel Dis 10 2004 751 757
7. J.B. Felder, B.I. Korelitz, R. Rajapakse Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease a case-control study Am J Gastroenterol 95 2000 1949 1954
8. J. Hendel, O.H. Nielsen Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease Am J Gastroenterol 92 1997 1170 1173
9. U. Mahadevan, E.V. Loftus Jr, W.J. Tremaine Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am J Gastroenterol 97 2002 910 914
10. R. Matuk, J. Crawford, M.T. Abreu The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease Inflamm Bowel Dis 10 2004 352 356
11. L. Biancone, C. Tosti, A. Geremia Rofecoxib and early relapse of inflammatory bowel disease an open-label trial Aliment Pharmacol Ther 19 2004 755 764
12. W. Reinisch, W. Miehsler, C. Dejaco An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia Aliment Pharmacol Ther 17 2003 1371 1380
13. W.J. Sandborn, W.F. Stenson, J. Brynskov A selective cyclooxygenase-2 inhibitor, celecoxib, is safe in patients with ulcerative colitis in remission Clin Gastroenterol Hepatol 4 2006 203 211
14. K. Takeuchi, S. Smale, P. Premshand Prevalance and mechanism of NSAID-induced clinical relapse in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 4 2006 196 202
15. D.J. Berg, J. Zhang, J.V. Weinstock Rapid development of colitis in NSAID-treated IL-10-deficient mice Gastroenterology 123 2002 1527 1542
16. H. Harizi, M. Juzan, V. Pitard Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions J Immunol 168 2002 2255 2263
17. M. Betz, B.S. Fox Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines J Immunol 146 1991 108 113
18. A. El-Medany, A. Mahgoub, A. Mustafa The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats Eur J Pharmacol 507 2005 291 299